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Pocal Release of C-Reactive Protein From Vulnerable
laque or Coronary Arterial Wall Injured by Stenting
eruo Inoue, MD, FACC,* Toru Kato, MD,* Toshihiko Uchida, MD,† Masashi Sakuma, MD,†
tsuko Nakajima, BSC,‡ Mitsuei Shibazaki, BSC,‡ Yoshitaka Imoto, BSC,§ Masahiko Saito, MD,
higemasa Hashimoto, MD,* Yutaka Hikichi, MD,* Koichi Node, MD*
aga, Koshigaya, Tokyo, and Ageo, Japan
OBJECTIVES The purpose of this study was to assess local release of C-reactive protein (CRP) from
atherosclerotic plaques or the vessel wall injured by stenting.
BACKGROUND Recent research has focused on the local production of CRP, especially in inflammatory
atherosclerotic plaques.
METHODS The study consisted of two separate protocols. In protocol 1, we measured serum high-
sensitivity-CRP (hs-CRP) levels in coronary arterial blood sampled just distal and proximal
to the culprit lesions in 36 patients with stable angina and 13 patients with unstable angina.
In protocol 2, we measured serial serum hs-CRP levels and activated Mac-1 on the surface
of neutrophils in both coronary sinus and peripheral blood in 20 patients undergoing coronary
stenting.
RESULTS In protocol 1, CRP was higher in distal blood than proximal blood in both stable (p  0.05)
and unstable angina (p  0.01). The translesional CRP gradient (distal CRP minus proximal
CRP, p  0.05) as well as the proximal CRP (p  0.05) and distal CRP (p  0.05) was
higher in unstable angina than in stable angina. In protocol 2, the transcardiac CRP gradient
(coronary sinus minus peripheral blood) and activated Mac-1 increased gradually after
stenting, reaching a maximum at 48 h (p  0.001 vs. baseline for both). There was a positive
correlation between the transcardiac CRP gradient and activated Mac-1 at 48 h (r  0.45, p
 0.01).
CONCLUSIONS C-reactive protein is an excellent marker for plaque instability or poststent inflammatory
status, and its source might be the inflammation site of the plaque or the coronary arterial wall
injured by stenting. (J Am Coll Cardiol 2005;46:239–45) © 2005 by the American College
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.04.029of Cardiology Foundation
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Suman C-reactive protein (CRP) is an acute-phase reac-
ant and has long been considered merely an innocent
ystander in the inflammatory process. High-sensitivity
RP (hs-CRP) is now recognized as a powerful predictor of
ardiovascular events, including stroke, coronary heart dis-
ase, peripheral vascular disease, and sudden cardiac death
1).
Inflammation plays an essential role in the initiation and
rogression of coronary atherosclerosis, as well as athero-
clerotic plaque rupture that culminates in acute coronary
yndromes (ACS) (2). Elevated circulating CRP commonly
ccompanies ACS, reflecting primary inflammation of vul-
erable plaques (3). In addition, percutaneous coronary
ntervention (PCI) produces a significant inflammatory
eaction in the injured vessel wall that leads to the devel-
pment of neointimal thickening and restenosis (4,5).
-reactive protein increases after PCI in a time-dependent
anner, with the maximum response at 48 h (6,7), and
redicts the occurrence of restenosis (8). In the process of
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ccepted April 14, 2005.nflammation at the site of the vessel wall injured by PCI,
eukocyte integrin Mac-1 (CD11b/CD18) plays a central
ole. Percutaneous coronary intervention induces activation
nd up-regulation of Mac-1 on the surface of neutrophils,
ith the maximum response at 48 h after PCI, and this is
lso associated with restenosis (9–14).
Not only is CRP a powerful inflammatory marker, but
ecent evidence suggests that CRP may also directly partic-
pate in the inflammatory process of atherogenesis. Al-
hough it is thought that CRP is produced mainly in liver,
eflecting a systemic inflammatory reaction (15), recent
RP research has focused on its localization in various
issues such as atherosclerotic plaques (16). However, it is
ot yet known if CRP is produced at the site of the
ulnerable plaque or the vessel wall injured by PCI and
hether locally released CRP plays any role in Mac-1
ctivation and restenosis.
In this study, we clinically assessed local CRP production,
rst at the vulnerable plaque and then at the site of vessel
all injured by PCI. We also assessed the relationship
etween local CRP production and activation of Mac-1 on
he surface of neutrophils leading to restenosis.
ETHODS
tudy protocol PROTOCOL 1. The subjects included 49
atients with atherosclerotic coronary artery disease who
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Local CRP Released From Inflamed Vessel Wall July 19, 2005:239–45nderwent PCI for an isolated culprit lesion. Of these 49
atients, there were 36 patients with stable angina and 13
atients with unstable angina (4 patients in class I B, 7 in
lass II B, and 2 in class III B according to Braunwald’s
lassification) but without angiographically detectable
hrombus in the culprit lesion. The PCI procedure was
erformed using the over-the-wire technique. Before the
CI procedure, a 2-ml blood sample was taken via the
alloon catheter when the catheter was advanced to a site
ust proximal to the target lesion. Next, a blood sample was
lso taken at a site just distal to the lesion after the catheter
rossed through the lesion (Fig. 1). The PCI procedure was
ompleted after collecting the two blood samples. Whole
lood was immediately collected into tubes containing
thylene diaminetetraacetate (EDTA).
ROTOCOL 2. The subjects included 20 patients with stable
ngina and isolated atherosclerotic coronary artery disease of
he proximal left anterior descending artery who underwent
nitial elective coronary stent implantation (April 1999 to
arch 2001) and follow-up coronary angiography. All
atients exhibited clinically stable class I or II effort angina
ithout previous myocardial infarction according to the
anadian Cardiovascular Society. None of these patients
ere included in protocol 1, but they were included among
he subjects in our previous study (14). The target lesions
ere all type A or type B lesions, as described by the
merican College of Cardiology/American Heart Associa-
ion Task Force. Patients were excluded who showed
Abbreviations and Acronyms
ACS  acute coronary symptoms
CRP  C-reactive protein
EDTA  ethylenediaminetetraacetic acid
hs-CRP  high-sensitivity C-reactive protein
MLD  minimal lumen diameter
PCI  percutaneous coronary intervention
igure 1. Translesional measurement of C-reactive protein (CRP). The
istal CRP was higher than the proximal CRP in the groups with stable
nd unstable angina. Thus, a translesional CRP gradient was present. Both
he proximal and distal CRP levels in unstable angina were higher than int
table angina. The translesional CRP in unstable angina was also greater
han in stable angina.o-reflow or slow-flow phenomena or post-PCI myocardial
amage demonstrated by elevation of creatine kinase-MB
sozyme level over twice the upper limit of the normal range.
he characteristics of the patients are shown in Table 1.
ercutaneous coronary intervention was performed using
he standard technique with a femoral approach. Coronary
esions were assessed by quantitative coronary angiographic
easurements. Reference diameter, lesion length, and min-
mal lumen diameter (MLD) were measured, and acute gain
MLD after PCI minus MLD before PCI) was determined.
ate lumen loss (MLD after PCI minus MLD at 6 months
f follow-up) was calculated as an index of neointimal
hickening. Before PCI, a catheter was positioned in the
oronary sinus and left for 48 h after the procedure for
oronary sinus blood sampling. Coronary sinus blood as well
s peripheral blood was collected before PCI and at 15 min,
4 h, and 48 h after coronary stenting. Whole blood was
mmediately collected into tubes containing acid citrate
extrose or EDTA.
In both studies, patients with acute or recent myocardial
nfarction and patients with a high CRP value (1.5 mg/dl)
ere excluded. All of the patients received standard daily
ral medications for angina, including 81 mg of aspirin, and
one of the medications was discontinued or exchanged
uring PCI or the follow-up period. Intravenous heparin
as administered to maintain an adequate activated clotted
ime during PCI and for 48 h after the procedure. In
rotocol 2, patients received 200 mg of oral ticlopidine 2
ays before PCI and for one month after PCI (this is the
urrent standard poststent antiplatelet regimen in Japan).
oth protocols were approved by the local ethics committee,
nd written informed consent was obtained from each
atient.
aboratory measurements. The EDTA blood was centri-
uged at 1,500 G for 15 min at room temperature for
easurement of hs-CRP. The plasma was frozen and stored
t 80°C until analysis. The hs-CRP was measured by
article-enhanced technology on the Behring BN II neph-
lometer (Dade Behring Inc., Newark, Delaware) (17). This
ssay used monoclonal anti-CRP antibodies and a calibrator
able 1. Patient Characteristics in Protocol 2
ge (yrs) 46–78 (63  12)
en/women 16/4
VD/MVD 11/9
iabetes 5 (25%)
ypertension 7 (35%)
otal cholesterol (mg/dl) 158–279 (210  44)
riglycerides (mg/dl) 76–523 (188  133)
DL cholesterol (mg/dl) 34–58 (45  11)
DL cholesterol (mg/dl) 74–172 (128  38)
tatin 4 (20%)
CEI 4 (20%)
RB 3 (15%)
CEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor
locker; HDL high-density lipoprotein; LDL low-density lipoprotein; MVD
ultivessel coronary artery disease; SVD  single-vessel coronary artery disease.hat was traceable to World Health Organization reference
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July 19, 2005:239–45 Local CRP Released From Inflamed Vessel Wallaterial. Using this method, the run-to-run coefficient of
ariation at hs-CRP concentrations of 0.047, 1.05, and 5.49
g/dl, was 6.4%, 3.7%, and 2.9%, respectively, and the
etection limit was 0.001 mg/dl (18).
The acid citrate dextrose whole blood was used for flow
ytometric analysis to measure the expression of the
ctivation-dependent neoepitope of Mac-1 on the surface of
eutrophils. We used a purified monoclonal antibody, 8B2
provided by Dr. Thomas Edgington, Department of Im-
unology, The Scripps Research Institute, La Jolla, Cali-
ornia) with a high sensitivity and specificity for the recog-
ition of the activation-dependent neoepitope of Mac-1
14,19). Purified mouse immunoglobulin G1 was also used
s an isotype-negative control. The fluorescein-conjugated
econd-step reagents used for indirect immunofluorescence
ere fluorescein isothiocyanate-conjugated F(ab=)2 frag-
ent of antimouse immunoglobulin G goat immunoglobu-
ins (Dako, Glostrup, Denmark). Indirect immunofluores-
ence labeling was performed on whole blood incubated
ith 8B2 (100 g/ml). The flow cytometric analysis was
erformed using an EPICS XL flow cytometer (Coultron-
cs, Sunnyvale, California). Cell surface antigen expression
as quantified using QIFIKIT (Biocytex, Marseille,
rance). The antibody binding capacity was measured as an
ndex of the 8B2 binding (i.e., expression of the activation-
ependent neoepitope of Mac-1) on the surface of neutro-
hils (14).
tatistical analysis. Values were expressed as the mean 
D. In both protocols, intergroup comparisons were per-
ormed using Student unpaired t test for continuous vari-
bles and the chi-square test for categorical variables.
ntragroup comparisons were performed using Student
aired t test. Serial changes in the variables were evaluated
y repeated measures analysis of variance for intra- and
ntergroup comparisons. Correlations between two param-
ters were assessed using simple linear regression. Multiple
egression analysis was performed for predicting late lumen
oss in protocol 2. A p value of 0.05 was considered
ignificant.
ESULTS
rotocol 1. There were no significant differences in age,
ender, coronary risk factors, or medications that might
ffect inflammatory status between the group with stable
ngina and the group with unstable angina (Table 2). The
istal CRP was higher than the proximal CRP in both
roups of patients. Thus, a translesional CRP gradient
distal CRP minus proximal CRP) was present in stable
ngina as well as unstable angina. Both the proximal and
istal CRP levels in the unstable angina group were higher
han in the stable angina group. Translesional CRP in the
nstable angina group was also greater than in the stable
ngina group (Fig. 1). In all patients, proximal CRP
orrelated with translesional CRP (r  0.62, p  0.001)
Fig. 2).
t
brotocol 2. The plasma CRP level increased after coronary
tenting from baseline in a time-dependent manner, reach-
ng a maximum at 48 h in both coronary sinus blood (0.18
0.11 mg/dl to 1.20  0.16 mg/dl, p  0.001) and
eripheral blood (0.12  0.01 mg/dl to 0.79  0.15 mg/dl,
 0.001). The changes in CRP levels were more striking
n the coronary sinus blood than peripheral blood (p 
.01). The transcardiac gradient of CRP increased after
CI, reaching a maximum at 48 h (0.06  0.18 mg/dl to
.40  0.20 mg/dl, p  0.001) (Fig. 3). The antibody
inding capacity for 8B2 (i.e., expression of Mac-1 activa-
ion neoepitope on the surface of neutrophils) began to
ncrease 15 min after coronary stenting and reached a
aximum at 48 h in both coronary sinus blood (5,080  80
ites/cell to 7,360  520 sites/cell, p  0.001) and periph-
ral blood (5,040  90 sites/cell to 6,320  320 sites/cell, p
0.01). The changes were also more striking in coronary
inus blood than peripheral blood (p  0.01). The trans-
ardiac gradient (coronary sinus blood minus peripheral
lood) of 8B2 binding also increased after PCI and reached
maximum at 48 h (40  140 sites/cell to 1,280  720
able 2. Patient Characteristics in Protocol 1
Stable
Angina
(n  36)
Unstable
Angina
(n  13)
p
Value
ge (yrs) 69  14 64  11 NS
en/women 28/8 9/4 NS
ingle-vessel CAD/
multivessel CAD
16/20 7/6 NS
arget lesion (LAD/LCX/RCA) 18/6/12 7/2/4 NS
moking 28 (78%) 10 (77%) NS
iabetes mellitus 13 (36%) 3 (23%) NS
ypertension 20 (56%) 6 (46%) NS
otal cholesterol (mg/dl) 198  42 204  34 NS
riglycerides (mg/dl) 142  86 146  80 NS
DL cholesterol (mg/dl) 49  16 47  14 NS
tatins 11 (31%) 4 (31%) NS
ngiotensin receptor blockers 12 (33%) 3 (23%) NS
AD  coronary artery disease; LCX  left circumflex artery; HDL  high-density
ipoprotein; LAD  left anterior descending artery; RCA  right coronary artery.
igure 2. Correlation between proximal C-reactive protein (CRP) and
ranslesional CRP. In all patients, there was a significant correlation
etween the two measurements.
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Local CRP Released From Inflamed Vessel Wall July 19, 2005:239–45ites/cell, p  0.001) (Fig. 4). The correlation between the
ranscardiac gradients of CRP and of 8B2 binding at each
ime point is shown in Figure 5. There was no significant
orrelation before PCI. However, positive correlations were
een at 15 min (r  0.31, p  0.06) and at 24 h (r  0.41,
 0.05) that reached borderline significance. There was a
ignificant positive correlation at 48 h (r  0.45, p  0.03).
ngiographic late lumen loss was predicted by the trans-
ardiac gradient of 8B2 (r  0.44, p  0.04) and by the
ranscardiac gradient of CRP (r  0.48, p  0.03) at 48 h
n a simple linear regression analysis (Fig. 6). A multiple
egression analysis that included all of the variables shown in
able 3 demonstrated that both 8B2 (r  0.43, p  0.03)
nd CRP (r  0.44, p  0.02) were powerful independent
redictors of late lumen loss.
ISCUSSION
n the present study, we demonstrated in protocol 1 that
RP was higher in blood sampled just distal to the site of
n atherosclerotic coronary artery lesion compared with
lood sampled at a site just proximal to the lesion. The
resence of this translesional CRP gradient might have been
ue to CRP produced in the atherosclerotic plaque. Both
igure 3. Serial changes in plasma C-reactive protein (CRP) levels after
ercutaneous coronary intervention (PCI). C-reactive protein increased
fter coronary stenting in a time-dependent manner, reaching a maximum
t 48 h in both coronary sinus and peripheral blood. These changes were
lso more striking in coronary sinus blood (left). The transcardiac gradient
f CRP increased after PCI reaching a maximum at 48 h (right). Closed
ircles  coronary sinus blood (CS); open circles  peripheral blood (P);
quares  transcardiac gradient. *p  0.05 vs. pre; **p  0.01 vs. pre; ***p
0.001 vs. pre; †p  0.01 CS vs. P.
igure 4. Serial changes in the expression of Mac-1 activation neo-epitope
8B2 binding) on the surface of neutrophils after PCI. Antibody binding
apacity (ABC) of 8B2 began to increase immediately after coronary
tenting reaching a maximum at 48 h in both coronary sinus and peripheral
lood. These changes were more striking in coronary sinus blood (left).
he transcardiac gradient (coronary sinus blood minus peripheral blood) of
B2 binding increased after PCI, reaching a maximum at 48 h (right).
losed circles  coronary sinus blood (CS); open circles  peripheral
lood (P); squares  transcardiac gradient. *p  0.05 vs. pre; **p  0.01
s. pre; ***p  0.001 vs. pre; †p  0.01 CS vs. P. PCI  percutaneous
oronary intervention.
o
phe proximal and distal CRP levels were higher and the
ranslesional CRP gradient was greater in unstable angina
han in stable angina. These results suggest that CRP
roduction increases in the plaque, reflecting inflammation
n the process of plaque instability. We further demon-
trated in protocol 2 that PCI produced an inflammatory
eaction, as demonstrated by increased CRP and Mac-1
ctivation on the surface of neutrophils, and that the
CI-induced maximum inflammatory reaction occurred
8 h after PCI. The PCI-induced CRP elevation and
ac-1 activation were greater in coronary sinus blood than
n peripheral blood. These transcardiac measurements
howed that CRP was produced and Mac-1 was activated
cross the vascular bed at the PCI site, indicating active
ocal inflammation in the vessel wall injured by PCI.
ocal CRP production in the atherosclerotic plaque or
essel wall. Although CRP, like other acute-phase pro-
eins, is synthesized by the liver in response to systemic
igure 5. Correlation between the transcardiac gradients (CS-P) of CRP
nd 8B2 binding at each time point. There was no significant correlation
efore PCI (upper left). However, positive correlations at 15 min (upper
ight) and at 24 h (lower left) reached borderline significance. There was
significant positive correlation at 48 h (lower right). CS coronary sinus
lood; P  peripheral blood; PCI  percutaneous coronary intervention.
igure 6. Relationship between angiographic late lumen loss and 8B2
inding or CRP. Late lumen loss correlated with the transcardiac gradient
f 8B2 binding at 48 h (left) and that of CRP (right). CRP  C-reactive
rotein.
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July 19, 2005:239–45 Local CRP Released From Inflamed Vessel Wallnflammation (15), a variety of cell types participate in CRP
roduction, and CRP has recently been found in human
therosclerotic plaque (16). Torzewski et al. (20) observed
hat CRP colocalized with the terminal complement com-
lex in atherosclerotic plaques. However, in that report the
uthors suggested that CRP was deposited from circulating
RP produced by the liver instead of local synthesis. In
ontrast, Yasojima et al. (21) suggested that cells in the
rterial wall synthesized CRP. Using in-situ hybridization
echniques, the authors showed that elongated muscle-like
ells inside the atherosclerotic plaque were positive for CRP.
n the findings by Ishikawa et al. (16,22), immunoreaction
f CRP was localized and CRP messenger ribonucleic acid
as expressed in vulnerable plaques, suggesting that CRP
as synthesized locally in the plaques. Calabró et al. (23)
emonstrated in their in vitro study that human coronary
rtery smooth muscle cells could produce CRP in response
o inflammatory cytokines. We believe that the translesional
radient of CRP in our study provides strong and direct
vidence for endogenous CRP production in coronary
therosclerotic plaques. Moreover, the magnitude of the
ranslesional CRP gradient may be the most powerful
ndicator of a vulnerable plaque. In addition, our results
howing an increased transcardiac gradient of CRP after
CI suggest that the vessel wall injured by PCI is partially
esponsible for CRP production.
ole of Mac-1 for inflammation in PCI-injured vessel
all. Percutaneous coronary intervention produces local
echanical vascular injury that promotes leukocyte recruit-
ent and vascular inflammation (4,5). Accumulating neu-
rophils and monocytes release a variety of inflammatory
ediators, including cytokines, chemokines, growth factors,
nd reactive oxygen intermediates. These mediators poten-
iate injury and promote smooth muscle cell proliferation,
igration, and extracellular matrix deposition (9,24).
ac-1 orchestrates the recruitment of leukocytes by pro-
able 3. Multiple Regression Analysis for Predicting
ngiographic Late Lumen Loss
Regression Coefficient p Value
ge (yrs) 0.086 0.522
en/women 0.135 0.422
iabetes (on/off) 0.364 0.052
ypertension (on/off) 0.193 0.108
DL cholesterol (mg/dl) 0.274 0.072
DL cholesterol (mg/dl) 0.225 0.086
tatin (on/off) 0.264 0.075
CEI (on/off) 0.143 0.149
RB (on/off) 0.098 0.554
eference diameter (mm) 0.064 0.587
esion length (mm) 0.216 0.097
LD before PCI (mm) 0.128 0.186
cute gain (mm) 0.148 0.138
ranscardiac 8B2 (sites/cell) 0.426 0.028
ranscardiac hs-CRP (mg/dl) 0.442 0.024
s-CRP  high-sensitivity C-reactive protein; MLD  minimal lumen diameter;
CI  percutaneous coronary intervention; other abbreviations as in Table 1.oting firm adhesion to, and transmigration across, fibrin- sgen and platelet ligands, such as GP Ib alpha (25) and
ossibly intercellular adhesion molecule-2 (26), present at
ites of vessel wall injury. Prior experimental and clinical
tudies have implicated Mac-1 in restenosis. Monoclonal
ntibody blockade (27) and the absence of Mac-1 (28)
educe neointimal thickening after experimental angioplasty
nd stenting. We demonstrated that PCI up-regulated
ac-1 expression on the surface of neutrophils that was
ssociated with the subsequent development of restenosis
10–14). Maximum up-regulation of Mac-1 was observed
8 h after PCI in our serial sample analysis up to 144 h after
CI (10). We further demonstrated that PCI promoted an
ctivation-dependent conformational change of existing
ac-1 on the surface of neutrophils before up-regulation of
ac-1 expression. Maximal Mac-1 activation was also
bserved 48 h after PCI and was similar to maximal Mac-1
p-regulation (14). Although the present study showed the
ame results as our previous work, an association between
ac-1 activation and CRP production at the site of PCI is
ew information. Both simple linear regression and multiple
egression analysis showed that CRP levels as well as Mac-1
ctivation predicted angiographic late lumen loss (i.e., neo-
ntimal thickening or restenosis).
easurement of hs-CRP. Laboratory, clinical, and epide-
iologic evidence demonstrate a role for inflammation in
therogenesis. Prospective data from a population of appar-
ntly healthy men (29) and women (30) indicate that baseline
evels of CRP predict the risk of cardiovascular events. The
urrent methods of CRP measurement are capable of measur-
ng CRP with a detection limit of 0.3 to 0.5 mg/dl. Although
his detection limit is adequate for the traditional clinical use of
RP in monitoring infection, more sensitive measurement
ethods are required for assessing and predicting cardiovascu-
ar risk in healthy populations. In the present study, we used
he BN II nepherometer to perform an ultrasensitive latex-
nhanced immunoassay for hs-CRP with a detection limit of
.001 mg/dl (18). During inflammation in the vulnerable
laques or post-PCI inflammatory reaction, an augmentation
f inflammatory activity takes place, and there is an upward
hift in the distribution of CRP values. Therefore, a highly
ensitive measurement method may not be needed. However,
n this study we had to evaluate small differences in CRP values
etween the proximal and distal sampling sites and between
he peripheral and coronary sinus blood in order to establish
he respective translesional and transcardiac gradients. Thus, a
ighly sensitive assay, such as latex nepherometry, was required
or this type of analysis.
RP as a functional protein in the post-PCI inflam-
atory process. In addition to CRP’s serving as a powerful
nflammatory marker, recent evidence suggests that it may
irectly participate in the inflammatory process of athero-
enesis. C-reactive protein is thought to inhibit endothelial
itric oxide synthase and NO generation, to activate nuclear
actor kappa B, and to up-regulate adhesion molecules such
s intercellular adhesion molecule-1 or vascular cell adhe-
ion molecule-1 and angiotensin receptors (31). Thus, CRP
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Local CRP Released From Inflamed Vessel Wall July 19, 2005:239–45ay be an important functional protein in the process of
therogenesis. We believe that our CRP data show not only
local production of CRP, but also suggest that CRP
roduced locally might act as a functional protein in the
nflammatory process, leading to plaque instability or post-
CI restenosis.
otential limitations. This study has several potential
imitations. Because CRP activates the complement system
32,33) and promotes thrombosis in transgenic mice (34),
here is a possibility that the translesional gradient of CRP
as caused by CRP-enriched thrombus. Although our
atients with unstable angina in protocol 1 had no angio-
raphically detectable thrombus, the possible participation
f thrombus-derived CRP cannot be excluded. Recent
tudies suggested that there are different types of vulnerable
laques besides culprit plaques in ACS patients. Ishikawa et
l. (22) reported that a transcardiac gradient of CRP was
resent not only in patients with unstable angina and stable
ngina but also in control subjects, indicating the possibility
f the vulnerable plaques besides the culprit lesion in stable
ngina patients and even in the control subjects. Although
he comparison between translesional CRP and transcardiac
RP could not be performed in protocol 1, the presence of
baseline transcardiac gradient (0.06  0.18 mg/dl) before
CI in protocol 2 raises the possibility of the presence of
onculprit vulnerable plaques. The reports from larger
linical trials showed that lesion length or stent length was
powerful predictor of angiographic late lumen loss. How-
ver, multiple regression analysis in protocol 2 showed that
esion length was of only borderline significance in predict-
ng late lumen loss. This may have been due to small sample
ize or the fact that only type A or B lesions were included.
n both protocols, we could not precisely assess whether
edical treatments such as statins influenced CRP or
ac-1 because only a small number of patents received such
edications. This possibility should be explored in future
rials with a larger number of patients.
onclusions: clinical implications. The presence of trans-
esional or transcardiac gradients of CRP in our two study
rotocols suggests that at least some amount of the CRP in
he serum was produced at the site of the lesion. This locally
roduced CRP may act as a promoter of the inflammatory
rocess in vulnerable plaques or the vessel wall injured by
CI. Thus, evaluation of the local CRP is very important to
ecognize plaque instability or the pathophysiology of PCI-
nduced injury and repair. However, both translesional and
ranscardiac CRP measurements require a complex tech-
ique such as intracoronary or coronary sinus sampling and
annot be performed as routine clinical laboratory tests. On
he other hand, our observation of a correlation between
ranslesional CRP and proximal CRP in protocol 1 indi-
ates that even systemic CRP may be a good surrogate of
ocally produced CRP, although proximal CRP was not
lways equal to systemic CRP. In addition, the measure-
ent of Mac-1 activation on the surface of neutrophilsequires an expensive, complex technique such as flowytometry, whereas the measurement of systemic CRP is
ery simple. The correlation between transcardiac gradients
f CRP and that of Mac-1 activation at 48 h post-PCI that
e observed in protocol 2 indicates that CRP may be an
ppropriate surrogate for Mac-1 activation at the time of the
eak inflammatory response after PCI. The measurement of
RP is very useful to understand the pathophysiology of
CS or the post-PCI inflammatory process. Because CRP
s a functional protein that may promote the inflammatory
rocess, CRP might also be a potential therapeutic target
or plaque stabilization in ACS or for the prevention of
estenosis after PCI.
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